BioCardia Regains Nasdaq Compliance Following $4.9 Million ATM Equity Offering

On June 12, 2026, BioCardia, Inc. announced that it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million for continued listing under Nasdaq Listing Rule 5550(b)(1). This follows a previous notification of non-compliance received on April 10, 2026. To address the deficiency, the company utilized its "At The Market" (ATM) offering agreement with H.C. Wainwright & Co. Between April 1, 2026, and June 5, 2026, BioCardia sold an aggregate of 4,004,330 shares of common stock at an average price of $1.27 per share. These transactions generated approximately $4.9 million in net proceeds after deducting fees and expenses. While the company currently believes its stockholders' equity exceeds the $2.5 million threshold, Nasdaq will continue to monitor ongoing compliance. If the company fails to demonstrate compliance in its next periodic report, it may face delisting. Previously, Nasdaq had granted the company an extension until October 7, 2026, to regain compliance based on a submitted plan.